ArticlePLoS pathogens2026
TRIM29 knockout pigs exhibit enhanced broad-spectrum disease resilience by amplifying type I interferon antiviral defenses.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering host-virus interaction networks in ALV infection: an integrative multi-omics perspective.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While production traits have seen accelerated genetic improvement through advanced breeding technologies, disease resilience phenotypes continue to pose significant challenges in livestock breeding system. Current gene editing technologies provide an effective and biosafe strategy to enhance livestock disease resilience through precise manipulation of host antiviral genes. In this study, we successfully generated disease-resilient pigs exhibiting broad-spectrum antiviral activity against multiple viruses, with no observed adverse effects on pig health. The E3 ubiquitin ligase TRIM29 functions as a negative regulator of type I interferon (IFN) signaling, thus representing a potential antiviral target. Knockdown of TRIM29 in PK15 cells significantly enhanced antiviral immunity against pseudorabies virus (PRV) and vesicular stomatitis virus (VSV) by augmenting type I IFN production. Translationally, we generated Trim29 knockout (KO) mice and confirmed their enhanced antiviral ability to both PRV and VSV infections. Subsequently, we produced TRIM29-KO pigs via gene editing coupled with somatic cell nuclear transfer. Compared to wild-type controls, the TRIM29-KO pigs exhibited significantly enhanced resilience to PRV infection, which was associated with elevated type I IFN levels in vivo. Furthermore, alveolar macrophages derived from TRIM29-KO pigs showed reduced susceptibility to infection with PRV, VSV, and transmissible gastroenteritis virus (TGEV), highlighting their potential broad-spectrum antiviral activity against multiple viral pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.